Agenus to host bot/bal program update at esmo 2023

Lexington, mass.--(business wire)--agenus inc. (nasdaq: agen), a leader in developing novel immunological agents to treat various cancers, today announced that the company will host a corporate event to discuss advancements in its botensilimab/balstilimab (bot/bal) program at the upcoming european society for medical oncology (esmo) conference on sunday, october 22, 2023. agenus will provide updates from the ongoing bot/bal clinical program, including in neoadjuvant colorectal cancer and pancre.
AGEN Ratings Summary
AGEN Quant Ranking